Karyopharm Therapeutics (KPTI) Inventory Average (2019 - 2026)

Karyopharm Therapeutics (KPTI) has reported Inventory Average for 8 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average fell 17.71% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $4.0 million (down 17.71% YoY), and the FY2025 full-year result was $4.4 million, up 12.79% from the prior year.
• Inventory Average steadied at $4.0 million in Q2 2026 per KPTI's latest filing, from $4.0 million in the prior quarter.
• Across five years, Inventory Average topped out at $4.9 million in Q2 2025 and bottomed at $2.9 million in Q1 2024.
• Historically, Inventory Average has averaged $3.9 million across 5 years, with a median of $4.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Inventory Average retreated 27.81% in 2024, then surged 63.59% in 2025.
• Over 5 years, Inventory Average stood at $4.2 million in 2022, then retreated by 27.44% to $3.1 million in 2023, then jumped by 53.07% to $4.7 million in 2024, then dropped by 14.95% to $4.0 million in 2025, then increased by 0.35% to $4.0 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $4.0 million, $4.0 million, and $4.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.